SCHEDULE: Fort Baker Capital Discloses 5.1% Stake in Oaktree III

Fort Baker Capital Management LP, along with Steven Patrick Pigott and Fort Baker Capital, LLC, has disclosed a 5.1% beneficial ownership stake in Oaktree Acquisition Corp. III Life Sciences.

Summary

• Fort Baker Capital Management LP, Steven Patrick Pigott, and Fort Baker Capital, LLC collectively reported beneficial ownership of 1,000,000 Class A ordinary shares of Oaktree Acquisition Corp. III Life Sciences.
• This represents a 5.1% stake in the company's Class A ordinary shares, based on 19,783,010 shares outstanding as of March 26, 2026.
• The reporting persons share both voting and dispositive power over all 1,000,000 shares.
• The shares were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the disclosure of a 5.1% stake by an investment adviser suggests institutional interest and confidence in Oaktree Acquisition Corp. III Life Sciences, without indicating any immediate control-related intentions.

Positives

• A significant institutional investor, Fort Baker Capital Management LP, has taken a 5.1% stake, potentially signaling confidence in Oaktree Acquisition Corp. III Life Sciences.
• The disclosure indicates the shares were acquired in the ordinary course of business, suggesting a passive investment strategy rather than an activist one.

Negatives

• The filing itself does not contain negative financial or operational information about Oaktree Acquisition Corp. III Life Sciences.

Risks

• The filing does not detail specific risks related to Oaktree Acquisition Corp. III Life Sciences' operations or financial health; it is a disclosure of ownership.

Future Outlook

The Schedule 13G filing does not provide any forward-looking statements or guidance from Oaktree Acquisition Corp. III Life Sciences or the reporting persons regarding the issuer's future performance or strategic direction.

Management Comments

• The filing is a disclosure of beneficial ownership by an external investment entity and does not contain direct quotes or paraphrased statements from Oaktree Acquisition Corp. III Life Sciences' management.

Industry Context

StockSavvy.ai notes that the disclosure of a new significant shareholder, particularly an investment adviser like Fort Baker Capital Management LP, can sometimes be interpreted by the market as a vote of confidence in the issuer's prospects. For a life sciences SPAC (Special Purpose Acquisition Company) like Oaktree Acquisition Corp. III Life Sciences, attracting institutional investment is crucial for its eventual de-SPAC transaction and future growth.

Comparison to Industry Standards

• StockSavvy.ai assesses that a 5.1% stake is a notable position for an institutional investor in a public company. While not an activist stake, it signifies a material investment.
• For example, similar disclosures by funds like BlackRock or Vanguard often involve stakes of 5% or more across various sectors, indicating a standard practice for significant portfolio allocations.
• This level of ownership is typically below the threshold that would trigger activist engagement, aligning with the reporting persons' certification of a passive investment.

Stakeholder Impact

• Shareholders: May view the entry of a new significant institutional investor as a positive sign of confidence, potentially leading to increased liquidity or stability.
• Management: The presence of a 5.1% shareholder, even a passive one, could lead to increased scrutiny or engagement, though the filing disclaims intent to influence control.

Next Steps

• The filing does not outline any specific future actions, events, or milestones for Oaktree Acquisition Corp. III Life Sciences or the reporting persons beyond the ongoing ownership.

Key Dates

Recommendation

While the disclosure of a new significant institutional investor is generally a positive signal, this Schedule 13G filing is purely an ownership disclosure and does not provide new fundamental information about Oaktree Acquisition Corp. III Life Sciences' operations, financial performance, or strategic direction. Investors should 'hold' and await further operational updates or financial results from the company to make a more informed investment decision, as this filing primarily indicates a passive investment by Fort Baker Capital.

Keywords

Oaktree Acquisition Corp. III Life Sciences, Fort Baker Capital Management, Steven Patrick Pigott, Schedule 13G, Beneficial Ownership, Class A ordinary shares, Investment Adviser, Institutional Investor, SEC Filing